Format

Send to

Choose Destination
PLoS One. 2017 Jun 1;12(6):e0178447. doi: 10.1371/journal.pone.0178447. eCollection 2017.

Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists.

Author information

1
Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France.
2
Department of Genomic Medicine, The University of Manchester, Manchester, United Kingdom.
3
GenEd Coordinating Centre, University of Manchester, Manchester, United Kingdom.
4
Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
5
Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
6
Women's Health Research, Münster Medical School, Münster, Germany.
7
APHM, Hôpital de la Timone, Service Biostatistique et Technologies de l'Information et de la Communication, Marseille, France.
8
Institut Paoli-Calmettes, UMR_S 912, Marseille, France.

Abstract

OBJECTIVE:

To develop a generic scale for assessing attitudes towards genetic testing and to psychometrically assess these attitudes in the context of BRCA1/2 among a sample of French general practitioners, breast specialists and gyneco-obstetricians.

STUDY DESIGN AND SETTING:

Nested within the questionnaire developed for the European InCRisC (International Cancer Risk Communication Study) project were 14 items assessing expected benefits (8 items) and drawbacks (6 items) of the process of breast/ovarian genetic cancer testing (BRCA1/2). Another item assessed agreement with the statement that, overall, the expected health benefits of BRCA1/2 testing exceeded its drawbacks, thereby justifying its prescription. The questionnaire was mailed to a sample of 1,852 French doctors. Of these, 182 breast specialists, 275 general practitioners and 294 gyneco-obstetricians completed and returned the questionnaire to the research team. Principal Component Analysis, Cronbach's α coefficient, and Pearson's correlation coefficients were used in the statistical analyses of collected data.

RESULTS:

Three dimensions emerged from the respondents' responses, and were classified under the headings: "Anxiety, Conflict and Discrimination", "Risk Information", and "Prevention and Surveillance". Cronbach's α coefficient for the 3 dimensions was 0.79, 0.76 and 0.62, respectively, and each dimension exhibited strong correlation with the overall indicator of agreement (criterion validity).

CONCLUSIONS:

The validation process of the 15 items regarding BRCA1/2 testing revealed satisfactory psychometric properties for the creation of a new scale entitled the Attitudes Towards Genetic Testing for BRCA1/2 (ATGT-BRCA1/2) Scale. Further testing is required to confirm the validity of this tool which could be used generically in other genetic contexts.

PMID:
28570656
PMCID:
PMC5453525
DOI:
10.1371/journal.pone.0178447
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center